Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center Phase 1b/2 trial of TT12, in combination with KEYTRUDA® (pembrolizumab) in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer

Next Previous
Trial Profile

A multi-center Phase 1b/2 trial of TT12, in combination with KEYTRUDA® (pembrolizumab) in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; TT 12 (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Tessa Therapeutics

Most Recent Events

  • 18 Apr 2019 New trial record
  • 15 Apr 2019 According to a Tessa Therapeutics media release, company has entered into an agreement with Merck to evaluate TT-12 in combination with KEYTRUDA in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top